← All trials
NCT07216690
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2026
- Primary completion
- Jan 1, 2028
- Completion date
- Jan 1, 2029
- First posted
- Oct 14, 2025
- Last posted
- Nov 13, 2025
- Enrollment
- 40
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityOfficial
- National Institute on Drug Abuse (NIDA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.